(Q40740817)

English

Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis

scientific article published on 25 March 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Brief Report: Secukinumab Provides Significant and Sustained Inhibition of Joint Structural Damage in a Phase III Study of Active Psoriatic Arthritis (English)

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Philip G Conaghan

5

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Désirée van der Heijde

1

object named as

Désirée van der Heijde

0 references

author name string

Robert B Landewé

2

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Philip J Mease

3

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Iain B McInnes

4

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Luminita Pricop

6

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Greg Ligozio

7

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Hanno B Richards

8

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Shephard Mpofu

9

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

publication date

25 March 2016

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

full work available at URL

http://eprints.whiterose.ac.uk/98522/

content deliverer

White Rose Research Online

0 references

Arthritis & Rheumatology

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

68

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

8

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

1914-1921

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129532

24 September 2017

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129532

24 September 2017

Managing patients with psoriatic disease: the diagnosis and pharmacologic treatment of psoriatic arthritis in patients with psoriasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129532

24 September 2017

Ustekinumab, an anti-IL-12/23 p40 monoclonal antibody, inhibits radiographic progression in patients with active psoriatic arthritis: results of an integrated analysis of radiographic data from the phase 3, multicentre, randomised, double-blind, pla

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129532

24 September 2017

Interleukin-17+CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129532

24 September 2017

Effect of different imputation approaches on the evaluation of radiographic progression in patients with psoriatic arthritis: results of the RAPID-PsA 24-week phase III double-blind randomised placebo-controlled study of certolizumab pegol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129532

24 September 2017

Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129532

24 September 2017

Risk of mortality in patients with psoriatic arthritis, rheumatoid arthritis and psoriasis: a longitudinal cohort study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129532

24 September 2017

Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129532

24 September 2017

Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129532

24 September 2017

Psoriatic arthritis imaging: a review of scoring methods

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129532

24 September 2017

Psoriatic arthritis: epidemiology, clinical features, course, and outcome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129532

24 September 2017

How to report radiographic data in randomized clinical trials in rheumatoid arthritis: guidelines from a roundtable discussion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129532

24 September 2017

Patients with psoriatic arthritis have worse quality of life than those with psoriasis alone.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129532

15 June 2018

Golimumab in psoriatic arthritis: one-year clinical efficacy, radiographic, and safety results from a phase III, randomized, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129532

19 August 2018

A simplified disease activity index for rheumatoid arthritis for use in clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5129532

19 August 2018

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/27014997

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Psoriatic arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/27014997

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression

1 reference

https://pubmed.ncbi.nlm.nih.gov/27014997

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/ART.39685

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

10.1002/ART.39685

0 references

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

23 September 2017

2-s2.0-84977760286

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40740817&oldid=1906315829"